{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:29:36Z","timestamp":1768685376542,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bioorg.2020.104421","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T06:17:44Z","timestamp":1603433864000},"page":"104421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Design, synthesis and antitumor activity of icotinib derivatives"],"prefix":"10.1016","volume":"105","author":[{"given":"Longfei","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.104421_b0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2020.104421_b0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2020.104421_b0015","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2020.104421_b0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2020.104421_b0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2016.09.039","article-title":"Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2","volume":"125","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/17476348.2.2.167","article-title":"Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment","volume":"2","author":"Schettino","year":"2008","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.bioorg.2020.104421_b0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/cncr.28561","article-title":"A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib","volume":"120","author":"Reckamp","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2020.104421_b0040","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016392","article-title":"A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report","volume":"98","author":"Yin","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bioorg.2020.104421_b0045","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","article-title":"Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer","volume":"16","author":"Tan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2020.104421_b0050","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2020.104421_b0055","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.bmc.2016.01.003","article-title":"Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M\/L858R mutant","volume":"24","author":"Qin","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0060","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","article-title":"Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer","volume":"79","author":"Murtuza","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2020.104421_b0065","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.3263702","article-title":"Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors","volume":"242","author":"Yaish","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2020.104421_b0070","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.bmcl.2015.01.060","article-title":"Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib","volume":"25","author":"Mathew","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.104421_b0075","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.21037\/tlcr.2019.06.05","article-title":"Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer","author":"Tanaka","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bioorg.2020.104421_b0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejmech.2018.01.090","article-title":"6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells","volume":"147","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.bmc.2011.10.085","article-title":"Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity","volume":"20","author":"Li","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0090","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejmech.2018.06.011","article-title":"Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR\/HER2 inhibitors","volume":"155","author":"Milik","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0095","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2020.104421_b0100","doi-asserted-by":"crossref","unstructured":"M.C. Garassino, O. Martelli, M. Broggini, G. Farina, S. Veronese, E. Rulli, F. Bianchi, A. Bettini, F. Longo, L. Moscetti, M. Tomirotti, M. Marabese, M. Ganzinelli, C. Lauricella, R. Labianca, I. Floriani, G. Giaccone, V. Torri, A. Scanni, S. Marsoni, T. trialists, Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial, Lancet Oncol, 14 (2013) 981-988.","DOI":"10.1016\/S1470-2045(13)70310-3"},{"key":"10.1016\/j.bioorg.2020.104421_b0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","article-title":"Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor displays potent efficacy in preclinical studies","volume":"76","author":"Tan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2020.104421_b0110","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejmech.2013.03.028","article-title":"Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-triazoles as potential apoptotic agents","volume":"63","author":"Majeed","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/acsmedchemlett.5b00418","article-title":"New colchicine-derived triazoles and their influence on cytotoxicity and microtubule morphology","volume":"7","author":"Thomopoulou","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.104421_b0120","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1021\/bc100272z","article-title":"Labeling live cells by copper-catalyzed alkyne\u2013azide click chemistry","volume":"21","author":"Hong","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0125","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1021\/jm300260v","article-title":"Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition","volume":"55","author":"R\u00f6hrig","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0130","doi-asserted-by":"crossref","unstructured":"L.-F. Mao, G.-Q. Xu, B. Sun, Y.-Q. Jiang, W.-P. Dong, S.-T. Zhang, J.-X. Shen, X. he, Design, Synthesis and Antibacterial Evaluation of Novel 1,2,3-Triazole Derivatives Incorporating 3\u2032-Deoxythymidine, Journal of Chemical Research, 41 (2017) 645-649.","DOI":"10.3184\/174751917X15094552081189"},{"key":"10.1016\/j.bioorg.2020.104421_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111700","article-title":"1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships","volume":"183","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127304","article-title":"Synthesis and anti-proliferative activity of a novel 1,2,3-triazole tethered chalcone acetamide derivatives","volume":"30","author":"Vanaparthi","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2020.104421_b0145","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1021\/acs.jmedchem.0c00636","article-title":"Azidothymidine \u201cclicked\u201d into 1,2,3-triazoles: first report on carbonic anhydrase-telomerase dual-hybrid inhibitors","volume":"63","author":"Berrino","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.104421_b0150","doi-asserted-by":"crossref","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"Chmielecki","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2020.104421_b0155","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1158\/1078-0432.CCR-06-0760","article-title":"Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels","volume":"12","author":"Helfrich","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2020.104421_b0160","article-title":"Apoptosis methods and protocols","volume":"282","author":"Brady","year":"2004","journal-title":"Humana Press Totowa"},{"key":"10.1016\/j.bioorg.2020.104421_b0165","unstructured":"J.D. Moyer., E.G. Barbacci., K.K. Iwata., B.B. Lee Arnold, A. Cnnningham., C. DiOrio., J. Doty., M.J. Morin., M.P. Moyer., M. Neveu., V.A. Pollack., L.R. Pustilnik., M.M. Reynolds., D. Sloan., A. Theleman., a.P. Miller., Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase, Cancer Res, 57 (1997) 4838-4848."},{"key":"10.1016\/j.bioorg.2020.104421_b0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0093-7754(03)70011-6","article-title":"Preclinical studies with Erlotinib (Tarceva)","volume":"30","author":"Akita","year":"2003","journal-title":"Semin. Oncol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820317193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820317193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:17:09Z","timestamp":1758615429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820317193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":34,"alternative-id":["S0045206820317193"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104421","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and antitumor activity of icotinib derivatives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.104421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104421"}}